000			nab a22 7a 4500
999			_c16826 _d16826
003			PC16826
005			20220504121644.0
008			220504b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_93032 _aNúñez Boluda, Asunción _eNeumología
245	0	0	_aBurden of serious fungal infections in Spain. _h[artículo]
260			_bClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, _c2015
300			_a21(2):183-9.
500			_aFormato Vancouver: Rodríguez Tudela JL, Alastruey Izquierdo A, Gago S, Cuenca Estrella M, León C, Miro JM et al; University of Manchester in association with the LIFE program. Burden of serious fungal infections in Spain. Clin Microbiol Infect. 2015 Feb;21(2):183-9.
501			_aPMID: 25658565
504			_aContiene 45 referencias
520			_aEstimates of the incidence and prevalence of serious fungal infections, based on epidemiological data, are essential in order to inform public health priorities given the lack of resources dedicated to the diagnosis and treatment of these serious fungal diseases. However, epidemiology of these infections is largely unknown, except for candidaemia and cryptococcosis. The aim of this work is to calculate the burden of serious fungal infections in Spain. All published epidemiology papers reporting fungal infection rates from Spain were identified. Where no data existed, we used specific populations at risk and fungal infection frequencies in those populations to estimate national incidence or prevalence, depending on the condition. Around 8.1 million people suffer a fungal infection every year. Most of them are skin or mucosal infections causing no deaths. Candidaemia is more common than in other European countries and has risen by 1.88-fold in frequency in the last decade (8.1 cases × 100,000). Good estimates of invasive aspergillosis (2.75 cases × 100,000) and mucormycosis (0.04 × 100,000) are available. Fungal infections with a high mortality such as invasive aspergillosis, candidaemia, Pneumocystis pneumonia and mucormycosis are not numerous in Spain, but they affect those with severe underlying diseases and are therefore linked to poor outcomes. Additional studies are required, especially for high burden diseases such as recurrent thrush in women (∼9000 cases × 100,000 women), allergic bronchopulmonary aspergillosis (126 cases × 100,000) and severe asthma with fungal sensitisation (198 cases × 100,000).
710			_988 _aServicio de Neumología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16826.pdf _ySolicitar documento
942			_2ddc _cART _n0